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Platelets play a central role in the atherosclerotic inflammatory response, thrombotic vascular occlusion,
microembolization, vasoconstriction, and plaque progression. Persistent platelet activation poses a serious
problem among patients with acute coronary syndromes (ACS) and those who have undergone percutaneous
coronary intervention (PCI), placing them at risk for ischemic events and subacute stent thrombosis. Patients
undergoing PCI are at risk for further ischemic events because of procedure-related platelet activation as well
as the inherent persistent platelet hyperreactivity and enhanced thrombin generation associated with ACS.
Persistent platelet activation following an acute coronary event and/or PCI supports incorporating
antiplatelet strategies into the standard medical management of such patients. In this clinical setting,
antiplatelet therapies are capable of improving outcomes. Aspirin, thienopyridines, and glycoprotein IIb/IIIa
inhibitors, the 3 major pharmacologic approaches to persistent platelet activation, target various levels of the
hemostatic pathways and thrombus formation.
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Introduction
This brief review focuses on the role of platelets
in atherosclerotic inflammatory response and persistent
platelet activation in the setting of acute coronary syndrome
(ACS), with a particular focus on patients undergoing percu-
taneous coronary intervention (PCI). The stage is set here
for subsequent articles in the supplement that examine the
contemporary use of platelet inhibitors in patients with ACS
and those undergoing PCI, and remaining unmet needs in
the field.
Atherosclerotic and Inflammatory Activities of Platelets
In addition to their well-described important role in
thrombotic vascular occlusion, platelets also participate
in microembolization and vasoconstriction, plaque pro-
gression, and systemic inflammatory responses associated
with ACS.1 Microembolization and resultant obstruction
of the microvasculature are correlated with unfavorable
long-term clinical prognosis.2 Despite successful revascu-
larization, microvascular obstruction, and platelet-induced
vasospasm contribute significantly to inadequate perfusion
and prolonged tissue ischemia in the myocardium. In
addition, microembolization results in decreased myocar-
dial contractility.3 Platelets play a role in the initiation of
atherosclerotic lesion formation, but contribute to plaque
progression as well. Platelets within established plaques
release a variety of growth factors (such as platelet-derived
growth factor) and chemokines into the microenvironment;
these activities can contribute to plaque progression.1
Inflammation is now recognized to have a central role
in all stages of atherothrombosis, including early athero-
genesis, lesion progression, and thrombotic complications
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of atherosclerosis.4 A number of proinflammatory medi-
ators are expressed by activated platelets, but CD40
ligand (CD40L) appears to be one of the most impor-
tant platelet-derived proinflammatory mediators. Platelet
CD40L interacts with CD40 on endothelial cells and
leukocytes, triggering tissue factor and adhesion recep-
tor expression and chemokine release. Platelets express-
ing CD40L thus induce inflammatory and procoagulant
responses in vascular cells. Also, by promoting the release
of matrix-degrading enzymes, CD40L might also contribute
to plaque destabilization.1,5
Persistent Platelet Activation in the Setting of Acute Coronary
Syndromes and Postpercutaneous Coronary Intervention
Standard pharmacological approaches used in patients who
undergo PCI are intended to prevent post-PCI thrombotic
complications by stabilizing atherosclerotic plaques at
the target lesion and other remote atherosclerotic sites.
Mechanical disruption of coronary plaques by denudation
of the arterial endothelium and subsequent exposure to
thrombogenic matrix proteins, in addition to underlying
atherothrombotic disease, results in platelet activation
during and following PCI. The PCI-mediated enhancement
of vascular injury and platelet activation may be important
causes of abrupt vessel closure, restenosis, and subacute
stent thrombosis.6–8
Patients undergoing PCI are at risk for further ischemic
events not only because procedure-related platelet activa-
tion occurs, but also due to the inherent persistent platelet
hyperreactivity and enhanced thrombin generation associ-
ated with ACS.9 For example, enhanced platelet reactivity in
patients with stable coronary artery disease has been demon-
strated via enhanced platelet surface expression of P-selectin
in response to stimulation with low concentrations of ago-
nists such as adenosine diphosphate (ADP) (Figure 1).10
Importantly, the thrombolysis in myocardial infarction
(TIMI) 12 trials suggested that activation of platelets con-
tinues long after clinical stabilization post-ACS. In that trial,
significantly elevated platelet activation was demonstrated
even 28 days following stabilization after an ACS (versus nor-
mal and patient controls; p<0.05 for both control groups).11
High platelet reactivity in patients undergoing PCI has also
been shown to be a risk factor for ischemic events following
PCI. The platelet reactivity in patients and recurrent events
(PREPARE) POST-STENTING study demonstrated higher
posttreatment ADP-induced aggregation in patients who suf-
fered ischemic events over a 6-month period compared with
patients without ischemic events (p = 0.02) (Figure 2).12
A number of studies suggest that high platelet reactivity is
associated with stent thrombosis (ST) in patients who have
undergone PCI.13,14 However, ST often presents as an acute













































































Figure 1: Platelet reactivity of patients with stable CAD (solid bars)
compared with control subjects (open bars) as determined by platelet
surface expression of P-selectin in response to exogenous agonist
stimulation. ∗p<0.01 †p<0.05. Reproduced with permission from Furman
et al.10
whether the high platelet reactivity is the cause of ST rather
than it being a manifestation of the ischemic event itself. A
recent study found that patients who had undergone stenting
and experienced ST had significantly higher ADP-induced
P-selectin expression and platelet aggregation compared
with patients who did not develop an ST. However, that
same study demonstrated a similarly high platelet reactivity
profile for patients with ST and patients with an acute ST
stent thrombosis-segment elevation myocardial infarction
(STEMI) treated with primary PCI.15 Regardless of the
remaining need for large prospective trials to determine
causation of platelet hyperreactivity in the case of ST, these
findings demonstrate further the high platelet reactivity that
is characteristic of ACS and in patients who undergo PCI.
The hyperthrombotic milieu observed post-PCI may persist


































Figure 2: ADP-induced posttreatment platelet aggregation (20 µM) as
measured by light transmittance aggregometry (LTA) in patients without
ischemic events and with ischemic events. Reproduced with permission
from Gurbel PA et al.12
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and long-term intervention with platelet inhibitors;16 thus,
antiplatelet therapy has become an integral component of
patient care in the peri and postprocedure period.
Antiplatelet Interventions Used in Acute Coronary Syndromes
Pharmacologic antiplatelet interventions target various lev-
els of the hemostatic pathways and thrombus forma-
tion (Figure 3).17 The 3 current approaches to medical
antiplatelet therapy used in patients with ACS are as follows:
• Aspirin (ASA): inhibits platelet activity via irreversible
acetylation of cyclooxygenase 1, preventing the
formation of thromboxane A2 –a potent mediator of
platelet aggregation
• Thienopyridines: inhibit ADP-mediated stimulation of
the P2Y12 receptor resulting in inhibition of platelet
activation and subsequently of platelet aggregation
processes.
• Glycoprotein (GP) IIb/IIIa inhibitors: the GP IIb/IIIa
receptor is a prothrombotic mediator of platelet
activation and aggregation. Following activation, GP
IIb/IIIa receptors are converted to a ligand-receptor
conformation. Once activated, this platelet receptor
binds the dimeric fibrinogen molecule and crosslinks
adjacent platelets, thereby causing aggregation.
Conclusion
Platelets are central to the process of normal hemosta-
sis. In the presence of coronary artery disease, they may
form thrombotic vascular occlusion at ruptured coronary
atherosclerotic plaque sites and also contribute substan-
tially to impairment of coronary microcirculation and ongo-
ing atherosclerotic inflammatory responses. The persistent
effect of platelet hyperreactivity following an acute coro-






































Figure 3: Interaction of platelets with components of thrombus formation and targets for pharmacological intervention. Reproduced with permission from
Kristensen SD et al.17
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antiplatelet strategies into the standard medical manage-
ment of such patients; these therapies have substantially
improved outcomes in certain patients in this setting. The
three major approaches to antiplatelet therapy in patients
with ACS have been briefly introduced here. In the next
article, landmark trials are reviewed that established cur-
rent antiplatelet approaches in patients with ACS and in
those undergoing PCI.
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